KR20190070946A - 바시트라신-알기네이트 올리고머 콘주게이트 - Google Patents

바시트라신-알기네이트 올리고머 콘주게이트 Download PDF

Info

Publication number
KR20190070946A
KR20190070946A KR1020197014051A KR20197014051A KR20190070946A KR 20190070946 A KR20190070946 A KR 20190070946A KR 1020197014051 A KR1020197014051 A KR 1020197014051A KR 20197014051 A KR20197014051 A KR 20197014051A KR 20190070946 A KR20190070946 A KR 20190070946A
Authority
KR
South Korea
Prior art keywords
bacitracin
alginate oligomer
alginate
conjugate
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197014051A
Other languages
English (en)
Korean (ko)
Inventor
일레인 퍼거슨
데이비드 윌리엄 토마스
아르네 데센
필립 라이
Original Assignee
알지파마 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알지파마 에이에스 filed Critical 알지파마 에이에스
Publication of KR20190070946A publication Critical patent/KR20190070946A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C07K7/58Bacitracins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
KR1020197014051A 2016-10-21 2017-10-20 바시트라신-알기네이트 올리고머 콘주게이트 Abandoned KR20190070946A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1617862.6 2016-10-21
GB1617862.6A GB2555391B (en) 2016-10-21 2016-10-21 Bacitracin-alginate oligomer conjugates
PCT/EP2017/076926 WO2018073448A1 (en) 2016-10-21 2017-10-20 Bacitracin-alginate oligomer conjugates

Publications (1)

Publication Number Publication Date
KR20190070946A true KR20190070946A (ko) 2019-06-21

Family

ID=57738026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014051A Abandoned KR20190070946A (ko) 2016-10-21 2017-10-20 바시트라신-알기네이트 올리고머 콘주게이트

Country Status (16)

Country Link
US (1) US20230139922A1 (enExample)
EP (1) EP3528829B1 (enExample)
JP (1) JP7191014B2 (enExample)
KR (1) KR20190070946A (enExample)
CN (1) CN109862904A (enExample)
AU (1) AU2017345294A1 (enExample)
BR (1) BR112019007928A2 (enExample)
CA (1) CA3040796A1 (enExample)
DK (1) DK3528829T3 (enExample)
ES (1) ES2914784T3 (enExample)
GB (1) GB2555391B (enExample)
PL (1) PL3528829T3 (enExample)
PT (1) PT3528829T (enExample)
RU (1) RU2766345C2 (enExample)
SI (1) SI3528829T1 (enExample)
WO (1) WO2018073448A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484473B (zh) * 2019-08-31 2022-08-19 暨南大学 一种促进鹤羽田戴尔福特菌在植物根际定殖的方法
CN111057131A (zh) * 2019-12-13 2020-04-24 上海市食品药品检验所 一种杆菌肽及其组分的分析方法
CN111420024B (zh) * 2020-04-07 2023-10-03 中国科学院深圳先进技术研究院 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113413490B (zh) * 2021-05-14 2022-05-27 哈尔滨医科大学 一种超声响应性复合水凝胶及其制备方法和应用
CN117679350B (zh) * 2023-12-13 2024-06-07 诺德溯源(广州)生物科技有限公司 一种淡化痘印和抚平痘坑的愈创木组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433593A (en) * 1972-06-09 1976-04-28 Royal College Of Surgeons Conjugates
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
PT2268142T (pt) * 2007-11-27 2017-06-02 Algipharma As Utilização de oligómeros alginados no combate aos biofilmes
EP2161020A1 (en) * 2008-09-09 2010-03-10 Koninklijke Philips Electronics N.V. Chelating amphiphilic polymers
RU2586253C2 (ru) * 2009-06-03 2016-06-10 АльгиФарма АС Обработка акинетобактерий альгинатными олигомерами и антибиотиками
JP6336902B2 (ja) * 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー.リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
WO2016081820A1 (en) * 2014-11-20 2016-05-26 University Of Southern California Use of alginate formulation for intraincisional drug delivery

Also Published As

Publication number Publication date
WO2018073448A1 (en) 2018-04-26
ES2914784T3 (es) 2022-06-16
CN109862904A (zh) 2019-06-07
EP3528829B1 (en) 2022-03-02
DK3528829T3 (da) 2022-05-30
GB2555391B (en) 2019-06-26
RU2019109728A3 (enExample) 2021-02-16
GB201617862D0 (en) 2016-12-07
BR112019007928A2 (pt) 2019-07-02
JP7191014B2 (ja) 2022-12-16
AU2017345294A1 (en) 2019-05-02
RU2766345C2 (ru) 2022-03-15
CA3040796A1 (en) 2018-04-26
SI3528829T1 (sl) 2022-07-29
GB2555391A (en) 2018-05-02
US20230139922A1 (en) 2023-05-04
RU2019109728A (ru) 2020-11-23
PT3528829T (pt) 2022-06-02
PL3528829T3 (pl) 2022-09-19
EP3528829A1 (en) 2019-08-28
JP2019535669A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
KR20190072579A (ko) 폴리믹신-알기네이트 올리고머 콘주게이트
KR20190070946A (ko) 바시트라신-알기네이트 올리고머 콘주게이트
CN103732232B (zh) 包含抗生素和分散剂或者抗粘结剂的组合物
US10751363B2 (en) Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
US20030008844A1 (en) Use of sulodexide for the treatment of inflammatory bowel disease
US10967065B2 (en) Compounds for treating biofilm infection
US20210121528A1 (en) Compositions for treating lung infections by airway administration
CA2516322A1 (en) Glycosaminoglycan-dnase combination therapy
JPS61186327A (ja) 感染防禦剤
WO2016012608A1 (en) Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
JP2022548005A (ja) 操作された細胞及びその使用
HK40004581A (en) Bacitracin-alginate oligomer conjugates
CA3168875A1 (en) Localized expression of therapeutic nucleic acids in lung epithelial cells
US20250352663A1 (en) Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use
HK40004580A (en) Polymyxin-alginate oligomer conjugates
Sun et al. Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904